Australia markets close in 5 hours 53 minutes

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
5.820.00 (0.00%)
At close: 10:29AM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.82
Open5.82
Bid0.00 x 0
Ask0.00 x 0
Day's range5.82 - 5.82
52-week range5.82 - 9.26
Volume500
Avg. volume5
Market cap146.124M
Beta (5Y monthly)1.56
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Poxel Announces Financial Calendar for 2022

    LYON, France, January 04, 2022--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its calendar for the publication of financial information for 2022.

  • Business Wire

    Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022

    LYON, France, December 14, 2021--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in January 2022.

  • Business Wire

    Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases

    LYON, France, December 06, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.